Day One Biopharmaceuticals inks research collaboration with Swedish biotech

Day One Biopharmaceuticals secured a research and licensing deal with Sprint Bioscience in a bid to build out its cancer-fighting arsenal.

The Bay Area biotech is paying $3 million upfront for the global rights of one of Sprint’s cancer programs known as VADA, which is designed to target the protein known as vaccinia-related kinase 1 or VRK1, which is prevalent in kidney, liver and pancreatic cancer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Wolf Creek is first Colorado ski area to open for the 2024-25 season – The Cannabist

Wolf Creek ski area will claim Colorado first-tracks honors Tuesday when it becomes the first Colorado ski area to open for the 2024-25 season. The

October 21, 2024

Kymera’s protein degrader starts Phase II trial in atopic dermatitis

Share this article The Phase II trials for KT-474 in AD and HS are expected to be completed in Q1 2025. Image Credit: IrinaFoto /

December 8, 2023

Hengrui and Kailera’s injected incretin posts best-in-class obesity data in Phase 2 trial

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 14, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.